Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)

Lupus

Volumn 15, Issue 4, 2006, Pages 191-197

  Cimaz, Rolando ^a,e   Meroni, P L ^b   Shoenfeld, Y ^c,d  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Antiphospholipid; Autoantibodies; Autoimmune; Epilepsy; Seizures; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; GLUTAMATE DECARBOXYLASE ANTIBODY; GLUTAMATE RECEPTOR 3; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; HUMAN; IMMUNOPATHOGENESIS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; SPONTANEOUS ABORTION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; EPILEPSY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33646272440     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2272rr     Document Type: Review

References (55)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (in press).
2. Shoenfeld Y. Systemic antiphospholipid syndrome. Lupus 2003; 12: 497-198.
3. Fisher RS, van Emde Boas W, Blume W et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-472.
4. Engel J. A proposed diagnostic scheme for people with seizures and with epilepsy; report of the ILAE Task Force on classification and terminology. Epilepsia 2001; 42: 796-803.
5. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-399.
6. Inzelberg R, Korczyn AD. The lupus anticoagulant and late onset seizures. Acta Neurol Scand 1989; 79: 114-118.
7. Verrot D, San-Marco M, Dravet C et al. Prevalence and significance of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33-37.
8. Debourdeau P, Gérome P, Zammit C et al. Frequency of anticardiolipin, antinuclear and anti-β2GP1 antibodies is not increased in unselected epileptic patients: a case-control study. Seizure 2004; 13: 205-207.
9. Sokol DK, McIntyre JA, Wagenknecht DR et al. Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology 2004; 62: 517-518.
10. Sokol DK, McIntyre JA, Short RA et al. Henoch-Schönlein purpura and stroke: antiphosphatidylethanolamine antibody in CSF and serum. Neurology 2000; 55: 1379-1381.
11. Ranua J, Luoma K, Peltola J et al. Anticardiolipin and antinuclear antibodies in epilepsy-a population-based cross-sectional study. Epilepsy Res 2004; 58: 13-18.
12. Peltola J, Palmio J, Korhonen L et al. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 2000; 42: 201-211.
13. Peltola JT, Haapala AM, Isojärvi JI et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000; 109: 712-717.
14. Pardo A, Gonzalez Porque P, Gobernado JM, Jimenez Escrig A, Lousa M. Study of antiphospholipid antibodies in patients treated with antiepileptic drugs. Neurologia 2001; 16: 7-10.
15. Spreafico R, Binelli S, Bruzzone MG et al. Primary antiphospholipid syndrome (PAPS) and isolated partial seizures in adolescence. A case report. Ital J Neurol Sci 1994; 15: 297-301.
16. Yoshimura K, Konishi T, Kotani H, Wakiguchi H, Kurashige T. Prevalence of positive anticardiolipin antibody in benign infantile convulsion. Brain Dev 2001; 23: 317-320.
17. Angelini L, Granata T, Zibordi F et al. Partial seizures associated with antiphospholipid antibodies in childhood. Neuropediatrics 1998; 29: 249-253.
18. Verrotti A, Greco R, Altobelli E, Latini G, Morgese G, Chiarelli F. Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients. Clin Exp Med 2003; 3: 32-36.
19. Cimaz R, Romeo A, Scarano A et al. Prevalence of anti-cardiolipin, anti-β2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002; 43: 52-59.
20. Eriksson K, Peltola J, Keränen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001; 46: 129-137.
21. Toubi E, Khamashta MA, Panarra A, Hughes GRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99: 397-401.
22. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GRV. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 568-571.
23. Afeltra A, Garzia P, Mitterhofer AP et al. Neuropsychiatric lupus syndromes. Relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-110.
24. Formiga F, Mitjavila F, Pac M, Moga I. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients. Lupus 1997; 6: 486.
25. Liou HH, Wang CR, Chen CJ et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5: 307-312.
26. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anticardiolipin and anti-β2 glycoprotein I antibodies in Indian patiens with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001; 10: 45-50.
27. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63: 1808-1812.
28. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005; 64: 2102-2107.
29. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature and case definitions for neuropsychiatric syndromes in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 599-608.
30. Tanne D, Hassin-Baer S. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheum Report 2001; 3: 286-292.
31. Shoenfeld Y, Lev S, Blatt I et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004; 31: 1344-1348.
32. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100: 613-619.
33. Caronti B, Pittoni V, Palladini G, Valesini G. Anti-β2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 1998; 156: 211-219.
34. Moore PM. Evidence for bound antineuronal antibodies in brains of NZB/W mice. J Neuroimmunol 1992; 38: 147-154.
35. Hess DC, Sheppard JC, Adams RJ. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke 1993; 24: 994-999.
36. Gilburd B, Stein M, Tomer Y et al. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: crossreactive or pathogenic? Autoimmunity 1993; 16: 23-27.
37. Caronti B, Calderaro C, Alessandri C et al. Serum anti-β2- glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998; 11: 425-429.
38. Kent MN, Alvarez FJ, Ng AK, Rote NS. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain. Exp Neurol 2000; 163: 173-179.
39. Kent M, Alvarez F, Bogt E. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol 1997; 24: 1725-1733.
40. Shoenfeld Y, Nahum A, Korczyn AD et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003; 12: 436-442.
41. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8: 127-133.
42. Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol 2005; 12: 175-180.
43. Liou HH, Wang CR, Chou HC et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994; 54: 1119-1125.
44. Xie XK, Tang LO. Observation on anti-brain antibody in serum of 110 epileptics. Chin Med J 1990; 103: 71-75.
45. Kwan P, Sills GJ, Kelly K, Butler E, Brodie MJ. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. Epilepsy Res 2000; 42: 191-195.
46. Peltola J, Kulmala P, Isojarvi J et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55: 46-50.
47. McKnight KBM, Jiang Y, Hart, Y et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65: 1730-1736.
48. Takahashi Y, Mori H, Mishina M et al. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia 2005; 46: 152-158.
49. Takahashi Y, Mori H, Mishina M et al. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 2003; 61: 891-896.
50. Mantegazza R, Bernasconi P, Baggi F et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002; 131: 179-185.
51. Wiendl H, Bien CG, Bernasconi P et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001; 57: 1511-1514.
52. Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res 2005; 65: 11-22.
53. Ganor Y, Goldberg-Stern H, Amromd D et al. Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy. Clin Dev Immunol 2004; 11: 241-252.
54. Ganor Y, Goldberg-Stern H, Blank M et al. Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome. Autoimmunity 2005; 38: 417-424.
55. Ranua J, Luoma K, Auvinen A et al. Antimitochondrial antibodies in patients with epilepsy. Epilepsy Behav 2005; 7: 95-97.